Medication info
Empagagmet 5/500 mg (Empagliflozin 2L-Proline, Metformin)

Empagagmet 5/500 mg (Empagliflozin 2L-Proline, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin 2L-Proline›7.55mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Kyungbo Pharmaceutical Co., Ltd.
Appearance
Pale yellow oval film-coated tablet
Packaging
30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 202502920 · Approved 2025.11.12

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined for each patient based on their current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose of this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's existing metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin to this medicine should receive their existing doses of empagliflozin and metformin. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you forget to take this medicine, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products of empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that can be administered with this medicine is 1000 mg, which may be administered as 500 mg twice daily. Renal function should be monitored carefully every 3-6 months (see Precautions for Use 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl <45 ml/min or eGFR <45 ml/min/1.73m2, discontinue this medicine immediately (see Precautions for Use 2. Patients in Whom the Medicine Must Not Be Administered, item 2)). Older adults In patients aged 75 years or older, renal function and the risk of volume depletion should be taken into consideration.

Ingredients

Manufacturer
Kyungbo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Abnormal blood sugar control in adult patients with Type 2 diabetes
  • cardiovascular disease
View approved original text

This medication is used as a combination therapy of Empagliflozin and Metformin to improve blood sugar control in adult patients with Type 2 diabetes, as an adjunct to diet and exercise. It can also be used in adult diabetic patients with cardiovascular disease when blood sugar is not adequately controlled. However, information regarding events related to cardiovascular events should be referenced from clinical trial data for professionals. This medication helps effectively manage blood sugar and prevent complications associated with diabetes.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined for each patient based on their current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose of this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's existing metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin to this medicine should receive their existing doses of empagliflozin and metformin. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you forget to take this medicine, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products of empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that can be administered with this medicine is 1000 mg, which may be administered as 500 mg twice daily. Renal function should be monitored carefully every 3-6 months (see Precautions for Use 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl <45 ml/min or eGFR <45 ml/min/1.73m2, discontinue this medicine immediately (see Precautions for Use 2. Patients in Whom the Medicine Must Not Be Administered, item 2)). Older adults In patients aged 75 years or older, renal function and the risk of volume depletion should be taken into consideration.

Precautions

This medication works by the combined action of its two components to help control blood sugar. First, it helps lower blood sugar by facilitating the excretion of glucose in urine through the kidneys. Additionally, the other component suppresses excessive glucose production in the liver and improves insulin action, contributing to blood sugar control. However, this medication should not be used in patients with poor kidney function. In particular, it is prohibited to administer in cases of moderate to severe decreased kidney function. It should also be avoided in acute illnesses such as severe infections, dehydration, congestive heart failure, and acute myocardial infarction. This medication is not administered to pregnant or breastfeeding women. During the use of this drug, symptoms of hypoglycemia may occur; hence, caution should be exercised regarding the risk of hypoglycemia when used in conjunction with insulin or other hypoglycemic agents. Additionally, this medication can cause a rare but serious side effect called lactic acidosis, so if symptoms such as sudden breathing difficulty, muscle pain, weakness, or abdominal pain occur, consult a doctor immediately. Urinary tract infections or genital infections can arise, so seek prompt treatment if related symptoms occur. This drug can cause a decrease in fluid volume; thus, caution is necessary if symptoms of dehydration or low blood pressure present themselves. Also, patients with liver impairment or those who consume excessive alcohol should be cautious when taking this medication. Before and after surgery or exams using iodine contrast agents, the use of this medication should be temporarily discontinued and resumed only after kidney function returns to normal. Elderly patients may have an increased risk of decreased kidney function; thus, renal function should be regularly monitored and dosages adjusted. This drug may lower vitamin B12 levels; therefore, monitoring serum vitamin B12 concentrations periodically during long-term use is advisable. In case of overdose, treatments like dialysis may be required, so dosage must be strictly adhered to. Finally, this medication has not been established for safety and efficacy in children under 18 years old and is not recommended for pediatrics.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased and deficiency of vitamin B12
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
Show 166 more
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function test
  • hepatitis
  • altered taste
  • itching
  • rash
  • hives
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • cystitis
  • vulvitis
  • balanitis
  • necrotizing fasciitis of the perineum
  • vascular stent stenosis
  • vascular stent thrombosis
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • pancreatic carcinoma
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • lower gastrointestinal bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • acute pyelonephritis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • headache
  • intracranial aneurysm
  • fever
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • ureterolithiasis
  • acute kidney injury
  • hematuria
  • hyperactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urine
  • vulvar pruritus
  • benign prostatic hyperplasia
  • erectile dysfunction
  • atrophic vulvitis
  • cervical dysplasia
  • cervical inflammation
  • scrotal pain
  • sexual dysfunction
  • vaginal discharge
  • hypoglycemia
  • decreased appetite
  • obesity
  • edema
  • diabetes
  • hyperlipidemia
  • hyponatremia
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • musculoskeletal pain
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • ocular congestion
  • pathological myopia
  • retinal detachment
  • retinal crystal bodies
  • retinal vein occlusion
  • exudative retinal detachment
  • eyelid edema
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • age-related dyspnea
  • wet cough
  • allergic rhinitis
  • residual phlegm
  • cough
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open eye injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • orthostatic dizziness
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • insomnia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture; therefore, it should be stored in a tightly closed container. Additionally, it is advisable to store it at room temperature between 1 to 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablet

Package unit

30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.